Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds

Not Applicable

Completed

Interventions: Device: Oxygen diffusing dressing
Device: Standard of care dressing

Brief Summary: This is a single-center, prospective, randomized, and controlled study to evaluate the effectiveness of OxyBand Dressing for the use as a dressing for autogenous skin donor sites compared to our current standard donor site dressing (Xeroform). Hypothesis is that the mean healing time for wounds treated with the OxyBand dressing will be less than the mean healing time for wounds treated with the Xeroform dressing.

Detailed Description: Patients who are scheduled for excision of burns or other injuries will have one of two donor sites covered with the OxyBand Dressing, and the other treated according to standard of care. OxyBand is an FDA (Food and Drug Administration) approved (K043063) wound dressing for delivery of oxygen into the wound. Two small clinical studies using OxyBand have been conducted on standardized laser burn wounds, demonstrating faster healing time compared to a placebo. No studies have compared this dressing to Xeroform dressing, the standard dressing used on donor sites in the USAISR.

Recruitment & Eligibility

Inclusion Criteria

Subject must be at least 18 years of age; of either gender and in good general health.
Subject has sustained burn wounds of less than 30 percent of the total body surface area
Burn wounds do not involve the harvesting area
Subject has sustained burn wounds that, in the judgment of the attending surgeon, require excision and grafting of sufficient extent to justify two donor sites of equal and symmetrical size on non-dependent body surfaces areas
The scheduled excision and grafting procedure is the first such operation for the subject during this hospitalization
Subject agrees to participate in follow-up evaluations

Exclusion Criteria

Critical illnesses such as those requiring ventilator support, or having a systemic infection or hemodynamic instability, defined as a mean arterial pressure less than 60 or requiring vasoactive medications to support blood pressure
Major acute or chronic medical illnesses that could affect wound healing (e.g. peripheral vascular disease, insulin dependent diabetes, blood clotting disorder)
Subjects receiving treatment with medications that inhibit or compromise wound healing. Examples include therapeutic anticoagulants, antiplatelet drugs, and systemic steroids such as warfarin, clopidogrel or prednisone. The use of anticoagulants does not include DVT (Deep Vein Thrombosis) prophylaxis. Subjects may use aspirin or lovenox
Cellulitis or other infection of the potential donor sites
Donor site has been previously harvested for grafting
Subjects with greater than 30% total body surface area burns
Pregnancy
Prisoners

Arm && Interventions

Group	Intervention	Description
Burn wound patients with donor sites	Oxygen diffusing dressing	Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)
Burn wound patients with donor sites	Standard of care dressing	Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)

Primary Outcome Measures

Name	Time	Method
Healing Time for Donor Site Wounds	number of days to healing	Wounds are inspected on postoperative days 4, 8, and then every two days until the wound is deemed to be healed.

Secondary Outcome Measures

Name	Time	Method
Pain Perceived by Patient	Post-Operative Day 4	Patient will be asked to rate pain 0-10 (0=no pain, 10=maximum pain) at the study site and the control site. Used Visual Analogue Scale (VAS) for this purpose.
Patient Will be Asked to Rate Pain 0-10/10 at the Study Site and the Control Site	Post-Operative Day 12